The 5 most recent market catalysts affecting $IMVT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 23, 2026
Corporate Catalyst
Bearish
Impact 95
Immunovant shares are trading lower after the company announced topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 did not achieve statistical significance on its primary endpoint.
The failure of IMVT-1402 to achieve statistical significance on its primary endpoint is a major setback for Immunovant. This directly impacts the company's valuation as a significa…
Sep 23, 2026
Corporate Catalyst
Neutral
Impact 75
Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint
Immunovant announced that its IMVT-1402 trial for cutaneous lupus erythematosus (CLE) did not meet its primary endpoint, leading to the discontinuation of development for this indi…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 92
Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate
Immunovant (IMVT) announced a Q1 loss of $(0.75) per share, which was substantially worse than the analyst consensus estimate of $(0.61) per share, representing a 22.95% miss. This…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Immunovant, Raises Price Target to $50
JP Morgan analyst Brian Cheng maintained an 'Overweight' rating on Immunovant (IMVT) and raised the price target from $47 to $50. This action signals a positive outlook from a prom…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.